Abstract
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are involved in normal B cell survival and differentiation. We analyzed BAFF and APRIL plasma levels in patients with B-cell chronic lymphocytic leukemia (B-CLL). We also tested intracellular BAFF and APRIL expression in B-CLL and evaluated their prognostic relevance. The percentage of leukemic B cells with intracellular APRIL or BAFF expression correlated significantly with adverse prognostic factors such as ZAP-70 and CD38. Moreover, we found a close relationship between LPL protein expression or LPL/ADAM29 MFI ratio and proportion of B-CLL cells with intracellular BAFF or APRIL expression. Furthermore, patients with a low percentage of leukemic cells with intracellular BAFF or APRIL expression had a significantly longer overall survival than those with a high proportion of APRIL or BAFF positive leukemic cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
B-Cell Activating Factor / blood
-
B-Cell Activating Factor / genetics*
-
B-Cell Activating Factor / metabolism
-
B-Lymphocytes / pathology
-
Female
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / blood
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
-
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
-
Male
-
Middle Aged
-
Neoplasm Staging
-
RNA, Neoplasm / genetics
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Analysis
-
Survivors
-
Tumor Necrosis Factor Ligand Superfamily Member 13 / blood
-
Tumor Necrosis Factor Ligand Superfamily Member 13 / genetics*
-
Tumor Necrosis Factor Ligand Superfamily Member 13 / metabolism
Substances
-
B-Cell Activating Factor
-
RNA, Neoplasm
-
TNFSF13 protein, human
-
TNFSF13B protein, human
-
Tumor Necrosis Factor Ligand Superfamily Member 13